Axel Bolte - 01 Jul 2025 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role: Director
Signature: /s/ Sanjay Subramanian, as attorney-in-fact for Axel Bolte
Issuer symbol: INZY
Transactions as of: 01 Jul 2025
Net transactions value: -$1,695,704
Form type: 4
Filing time: 03 Jul 2025, 19:07:07 UTC
Previous filing: 20 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bolte Axel	Director	C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON	/s/ Sanjay Subramanian, as attorney-in-fact for Axel Bolte	03 Jul 2025	0001579247

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INZY	Common Stock	Disposition pursuant to a tender of shares in a change of control transaction	$1,695,704	-423,926	-100%	$4.00	0	01 Jul 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INZY	Stock Option (Right to Buy)	Disposed to Issuer		-234,176	-100%		0	01 Jul 2025	Common Stock	234,176	$2.02	Direct	F1, F3
transaction	INZY	Stock Option (Right to Buy)	Disposed to Issuer		-159,187	-100%		0	01 Jul 2025	Common Stock	159,187	$2.77	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Axel Bolte is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger")
F2	Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F3	Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.